Details of the Drug

General Information of Drug (ID: DMAHOVJ)

Drug Name
Crizanlizumab
Synonyms SEG101
Indication
Disease Entry ICD 11 Status REF
Vaso-occlusive crisis BE2Y Approved [1]
Sickle-cell disorder 3A51 Phase 4 [2]
Drug Type
Antibody
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 34600 mgh/L [3]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 160 mg/L [3]
Clearance
The clearance of drug is 11.7 mL/h in healthy subjects [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 10.6 days [3]
Metabolism
The drug is metabolized via the into smaller peptides and amino acids [3]
Vd
The volume of distribution (Vd) of drug is 4.26 L [3]
Cross-matching ID
DrugBank ID
DB15271
TTD ID
DU47SF
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
P-selectin (SELP) TTE5VG0 LYAM3_HUMAN Inhibitor [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Vaso-occlusive crisis
ICD Disease Classification BE2Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
P-selectin (SELP) DTT SELP 1.72E-04 1.23 0.86
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
2 ClinicalTrials.gov (NCT04662931) An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients. U.S. National Institutes of Health.
3 FDA Approved Drug Products: Adakveo Crizanlizumab-TMCA Intravenous Injection
4 Crizanlizumab: First Approval. Drugs. 2020 Jan;80(1):79-84.